消融与手术治疗T1a肾细胞癌的远期结局相当:一项丹麦全国性登记研究
该回顾性全国登记队列研究纳入2013年1月至2021年12月丹麦诊断为T1a肾细胞癌的成人患者1862例,比较消融、手术切除与肾切除术的远期结局。调整混杂因素后,消融与手术切除的进展风险无显著差异(HR 1.46,95%CI 0.60-3.56,P=0.40);消融组局部复发最多(2.41% vs 1.20% vs 0%,P=0.007)但可追加治疗,肾切除术组远处转移最多(4.38% vs 1.67% vs 1.90%,P=0.02)。消融组住院时间最短、30天治疗后医院接触最少。
要点
- T1a肾细胞癌消融后进展风险与手术切除相当(HR 1.46,95%CI 0.60-3.56,P=0.40)。
- 消融组局部复发率2.41%(13/540),高于手术切除1.20%(12/1002)和肾切除0%(0/320),P=0.007。
- 消融组住院中位0天,短于手术切除和肾切除的2天(P<0.001)。
核心结论
- 在T1a肾细胞癌患者中,消融治疗的进展风险与手术切除相当,且并发症更少、住院时间更短。
研究设计与样本
- 回顾性全国登记队列研究,纳入2013年1月至2021年12月丹麦诊断为T1a肾细胞癌的成人患者1862例(中位年龄64岁,IQR 55-71岁;男性1305例),按治疗方式分为消融组、手术切除组和肾切除术组。
诊断标准与关键数值
- 主要结局为进展(远处转移或局部复发),采用竞争风险回归分析,报告风险比及P值;组间比较采用χ2检验和Wilcoxon秩和检验。
临床应用与阅片要点
- 消融组局部复发最多(13/540,2.41%),但可追加治疗;肾切除术组远处转移最多(14/320,4.38%),消融组9/540(1.67%),手术切除组19/1002(1.90%),P=0.02。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Incidental diagnosis of small renal masses is placing increasing pressure on health care systems. While surgical resection remains standard, ablation has emerged as a less invasive alternative, potentially reducing complications, hospital stays, and costs. However, knowledge about outcomes following ablation remains limited. Purpose To compare the long-term outcomes of ablation, surgical resection, and nephrectomy in patients with T1a renal cell carcinoma (RCC). Materials and Methods This retrospective nationwide-registry cohort study included Danish adults diagnosed with T1a RCC between January 2013 and December 2021. Patients were treated with tumor ablation, surgical resection, or nephrectomy. The primary outcome was progression, defined as distant metastasis or local recurrence. Secondary outcomes included hospital length of stay and 30-day posttreatment hospital contacts, excluding routine scheduled follow-up visits. Progression was analyzed using competing risk regression, and hazard ratios with P values are reported. The χ2 test and Wilcoxon rank sum test were used for other group comparisons. Results A total of 1862 patients (median age, 64 years [IQR, 55-71 years]; 1305 male patients) were included. There was no evidence of a difference in progression risk between the ablation and resection groups after adjusting for confounders (hazard ratio, 1.46 [95% CI: 0.60, 3.56]; P = .40). Local recurrence was most frequent following ablation (ablation: 13 of 540 patients [2.41%]; resection: 12 of 1002 [1.20%]; nephrectomy: zero of 320 [0%]; P = .007), but was treatable with additional procedures. Distant metastasis was most frequent following nephrectomy (ablation: nine of 540 patients [1.67%]; resection: 19 of 1002 [1.90%]; nephrectomy: 14 of 320 [4.38%]; P = .02). Hospital stays were shortest for ablation (median hospitalization time: 0 days for ablation, 2 days for resection, 2 days for nephrectomy; P < .001). Ablation resulted in the fewest 30-day posttreatment hospital contacts (median number of contacts: one [IQR, 0-2] for ablation, one [IQR, 1-2] for resection, one [IQR, 1-2] for nephrectomy; P = .001), suggesting fewer complications with ablation. Conclusion In patients with T1a RCC, treatment with ablation demonstrated comparable progression risk but with fewer complications and shorter hospital stays. © The Author(s) 2026. Published by the Radiological Society of North America under a CC BY 4.0 license. Supplemental material is available for this article.
引用
- Ahrenfeldt J, Jespersen J, Tonnesen P, et al. Ablation and Surgery Show Comparable Long-term Outcomes for T1a Renal Cell Carcinoma: A Danish Nationwide Registry Study. Radiology. 2026. PMID: 41773967. doi:10.1148/radiol.251485
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。